<DOC>
	<DOCNO>NCT00060359</DOCNO>
	<brief_summary>This phase I trial study side effect best dose polyglutamate paclitaxel give together carboplatin treat patient ovarian epithelial , peritoneal , fallopian tube cancer . Drugs use chemotherapy polyglutamate paclitaxel carboplatin use different way stop tumor cell divide stop grow die . Polyglutamate paclitaxel may able deliver drug directly tumor cell leave normal cell undamaged . Combining polyglutamate paclitaxel carboplatin may kill tumor cell .</brief_summary>
	<brief_title>Polyglutamate Paclitaxel Carboplatin Treating Patients With Ovarian Epithelial , Peritoneal , Fallopian Tube Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) polyglutamate paclitaxel combination carboplatin patient chemotherapy-na√Øve ovarian epithelial , primary peritoneal , fallopian tube carcinoma . II . Determine feasibility regimen MTD expand cohort patient . III . Determine response rate progression-free survival patient treat regimen expand cohort . IV . Determine toxicity profile regimen patient . V. Determine pharmacokinetics pharmacodynamics drug combination patient . OUTLINE : This open-label , multicenter , dose-escalation study polyglutamate paclitaxel ( CT-2103 ) follow feasibility , multicenter study . DOSE-ESCALATION PHASE : Patients receive CT-2103 IV 10 minute carboplatin IV 30 minute day 1 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos CT-2103 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity first course treatment . FEASIBILITY PHASE : Once MTD CT-2103 determine , additional 20-40 patient receive treatment dose level combine carboplatin . Patients follow every 3 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Endometrioid</mesh_term>
	<mesh_term>Cystadenocarcinoma</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Brenner Tumor</mesh_term>
	<mesh_term>Cystadenocarcinoma , Serous</mesh_term>
	<mesh_term>Cystadenocarcinoma , Mucinous</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically confirm ovarian epithelial , primary peritoneal , fallopian tube carcinoma Stage III IV Optimal ( great 1 cm ) suboptimal residual disease initial surgery The follow histologic epithelial cell type eligible : Serous adenocarcinoma Mucinous adenocarcinoma Clear cell adenocarcinoma Transitional cell carcinoma Adenocarcinoma otherwise specify Endometrioid adenocarcinoma Undifferentiated carcinoma Mixed epithelial carcinoma Malignant Brenner tumor No epithelial tumor low malignant potential ( borderline tumor ) Surgery perform within past 12 week Performance status GOG 02 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 No active bleeding Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 2.5 time ULN ( 5 time ULN liver metastasis ) Alkaline phosphatase great 2.5 time ULN ( 5 time ULN liver metastasis ) No acute hepatitis PT PTT normal Creatinine great 1.5 time ULN Cardiac conduction abnormality ( e.g. , bundle branch block heart block ) allow provide cardiac status stable past 6 month No myocardial infarction within past 6 month No unstable angina Not pregnant nursing Fertile patient must use effective contraception No neuropathy ( sensory motor ) grade 2 bad No invasive malignancy within past 5 year except nonmelanoma skin cancer localize breast cancer No active infection require antibiotic No circumstance would preclude study completion followup More 3 year since prior adjuvant chemotherapy localize breast cancer ( must free recurrent metastatic disease ) More 3 year since prior radiotherapy localize cancer breast , head neck , skin ( must free recurrent metastatic disease ) No prior radiotherapy portion abdominal cavity pelvis No prior treatment , debulking surgery , cancer No prior treatment another cancer would contraindicate protocol therapy No concurrent amifostine protective reagent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>